CTSA INFRASTRUCTURE FOR AIDS RESEARCH

本分项目是CTSA供资的估计百分比，即 被用于广泛的研究领域(艾滋病研究、儿科研究或 临床试验)。列出的总成本仅是对CTSA金额的估计 用于这一研究领域的基础设施，而不是由 授予子项目或子项目工作人员的NCRR补助金。 描述(由申请者提供)：在过去的一个周期中，在与我们的内部和外部咨询委员会、组织治理结构和NCRR的领导层进行协商后，我们将努力集中在两个主要主题上-转化性治疗和利用我们机构特有的资源弥合儿科与成人之间的鸿沟。我们通过一系列“自上而下”和“自下而上”的资助计划，促进了跨学科和转化性研究。CTSA的支持和机构投资使ITMAT的足迹大幅增加了7倍以上，达到约150,000 NSF，包括一个扩展、整合和重新定位的临床和翻译研究中心(CTRC)，接替宾夕法尼亚大学和CHOP GCRC，干湿工作台实验室空间，一系列核心和ITMAT教育项目的新址。ITMAT还支持研讨会、研讨会和年度国际会议，突出CTSA在我们校园内提供的从事临床和转化性研究的机会。在过去的供资周期中，伙伴机构内部、伙伴机构之间和伙伴机构之间的跨学科研究大幅增加，这些趋势在ITMAT成员中最为明显。在接下来的周期中，我们预计我们的教育项目将继续增长和发展；通过招聘和教育，临床和转化性研究的研究人员数量将继续扩大；我们的核心基础设施将得到增强和扩大；围绕我们的两大主题的计划将得到发展和扩大。特别是，我们希望通过提出我们的两个战略目标来影响社区的患者护理，这两个战略目标是通过整合基础、儿科和成人药理学的专业知识来改变当前比较有效性研究的范式，并为医学个性化的预测战略做出贡献。 相关性(由申请者提供)：宾夕法尼亚大学、CHOP、Monell、Wistar Institute和费城科学大学从CTSA的第一轮资助中受益匪浅，这使得CTSA能够开发新的中心、研究计划、核心和强大的教育计划，涉及校园和合作机构的800多名研究人员，并增加了全国范围内的联合活动。

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. DESCRIPTION (provided by applicant): During the past cycle, following consultation with our internal and external advisory boards, organizational governance structure and the leadership of NCRR, we have focused our efforts on two overarching themes - Translational Therapeutics and Bridging the Pediatric to Adult Divide, taking advantage of resources particular to our institutions. We have fostered interdisciplinary and translational research by a series of "top down" and "bottom up" funding initiatives. CTSA support and institutional investment has increased dramatically the footprint of ITMAT more than 7 fold to ~150,000 nsf comprising an expanded, integrated and re-purposed Clinical and Translational Research Center (CTRC) that succeeds the Penn and CHOP GCRCs, dry and wet bench laboratory space, a series of cores and a new home for ITMAT educational programs. ITMAT also supports seminars, workshops and an annual international meeting highlighting the opportunities that the CTSA affords on our campus to pursue clinical and translational research. Interdisciplinary research has increased dramatically on, between, and within the partner institutions during the past funding cycle and these trends have been most pronounced amongst members of ITMAT. During the coming cycle we envisage the continued growth and development of our educational programs; the continued expansion - via recruitment and education - of the critical mass of investigators pursuant of clinical and translational research; enhancement and expansion of our core infrastructure and the development and expansion of programs focused on our two overarching themes. In particular we hope to impact patient care in the community by projecting our two strategic goals to alter the current paradigm of comparative effectiveness research by integrating expertise in basic, pediatric and adult pharmacology and to contribute to predictive strategies in the personalization of medicine. RELEVANCE (provided by applicant): PENN, CHOP, Monell, Wistar Institute, and the University of the Sciences of Philadelphia have benefited greatly from the first cycle of funding of the CTSA, which allowed the development of new centers, research programs, cores and a robust educational program which involve more than 800 investigators across campus and from partner institutions, as well as adding to consortial activities nationally.